1 – Smith [37]
|
Normal
|
HD - 2 h
|
3.1 mg/g
|
1.0 mg/g
|
3.4 mg
|
n/a
|
Died
|
2
|
Normal
|
HD - 2 h
|
2.7 mg/g
|
1.3 mg/g
|
3.0 mg
|
n/a
|
Improved encephalopathy
|
3
|
Normal
|
HD - 30 min
|
1.6 mg/g
|
1.1 mg/g
|
1.0 mg
|
n/a
|
Remained severely encephalopathic
|
4
|
Normal
|
HD - 2 h
|
1.8 mg/g
|
0.7 mg/g
|
2.2 mg
|
n/a
|
Died
|
1 – Mehbod [38]
|
GFR < 10
|
CAPD
|
n/a
|
n/a
|
16.9 mg/20 h
|
0.12 mg/20 h
|
Weakness; constipation and anaemia improved
|
2
|
Normal
|
CAPD
|
n/a
|
n/a
|
1.90 mg/20 h
|
0.50 mg/20 h
|
No immediate improvement; no long-term follow up
|
3
|
Normal
|
CAPD
|
n/a
|
n/a
|
1.48 mg/20 h
|
0.70 mg/20 h
|
No immediate improvement; no long-term follow up
|
4
|
Normal
|
CAPD
|
1.25 mg/L
|
0.75 mg/L
|
2.00 mg/20 h
|
0.40 mg/20 h
|
Improved encephalopathy; no long-term follow up
|
1 – Pedersen [39]
|
Normal
|
HD – 9 h
|
1.36 mg/L
|
0.68 mg/L
|
n/a
|
n/a
|
Serum Pb level 0.28 mg/L after 7 weeks; no clinical outcome reported
|
1 – Roger [40]
|
ESKF
|
CAPD
|
1.40 μmol/L
|
n/a
|
9.29 μmol over 4 days
|
2.96 μmol/day on day 4
|
Improved mental state but peripheral neuropathy progressed after 4 months
|
1 – Kessler [41]
|
ESKF
|
HF
|
0.279 mg/L
|
n/a
|
1.650 mg/day a
|
n/a
|
2
|
ESKF
|
HF
|
0.131 mg/L
|
n/a
|
1.450 mg/day a
|
n/a
|
3
|
ESKF
|
HF
|
0.361 mg/L
|
n/a
|
1.152 mg/day a
|
Died
|
4
|
ESKF
|
HF
|
0.281 mg/L
|
n/a
|
1.267 mg/day a
|
n/a
|
5
|
ESKF
|
CAPD
|
0.265 mg/L
|
n/a
|
0.334 mg/day
|
0.476 mg/day
|
n/a
|
1 – Kessler [42]
|
ESKF
|
HF
|
0.280 mg/L
|
n/a
|
3.300 mg/day a
|
n/a
|
2
|
ESKF
|
CAPD
|
0.265 mg/L
|
n/a
|
0.710 mg/day a
|
n/a
|
1 – Barats [43]
|
ESKF
|
HD
|
0.690 mg/L
|
0.110 mg/Lb
|
n/a
|
n/a
|
Resolved encephalopathy and motor neuropathy
|
1 – Roberts [44]
|
ESKF
|
HD
|
0.49 μg/L
|
n/a
|
0.24 mg
|
0.025 mg
|
Lead mobilisation test
|